Skip to content
phase 2Weight Loss & Diabetes

Danuglipron

Also known as: PF-06882961, Pfizer oral GLP-1

Danuglipron is an oral, non-peptide small molecule GLP-1 receptor agonist developed by Pfizer. Unlike injectable peptide-based GLP-1 RAs, danuglipron is a fully synthetic compound designed to be taken as a pill. Phase 2 trials demonstrated HbA1c reductions of up to 1.16% and weight loss of 4–10 kg over 16–32 weeks. Pfizer pivoted to a modified-release once-daily formulation after the twice-daily version showed high discontinuation rates due to gastrointestinal side effects.

4 cited references·5 researched benefits

Quick Answer

Danuglipron is an oral small molecule GLP-1 receptor agonist developed by Pfizer — not a peptide but a synthetic compound that activates the same GLP-1 receptor as semaglutide and liraglutide. Phase 2 trials showed HbA1c reductions up to 1.16% and weight loss of 4–10 kg. Development focuses on a once-daily modified-release formulation to improve tolerability. If successful, it could offer a non-injectable, potentially lower-cost alternative to peptide GLP-1 RAs.

Key Facts

Mechanism
Danuglipron is a non-peptide, orally bioavailable agonist of the GLP-1 receptor (GLP-1R). Unlike peptide-based GLP-1 RAs, it does not require protection from proteolytic degradation. It binds to an allosteric site on the GLP-1R extracellular domain, inducing a conformational change that activates the receptor and triggers downstream cAMP signaling in pancreatic beta cells, leading to glucose-dependent insulin secretion. It also engages central GLP-1 receptors in the hypothalamus and brainstem to suppress appetite and reduce food intake. As a small molecule, it may have different receptor engagement kinetics compared to peptide agonists, potentially affecting efficacy and side effect profiles.
Research Status
phase 2
Half-Life
~6–8 hours (immediate-release); extended with modified-release formulation
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Oral administration — no injections required, potentially improving patient adherence and accessibilitystrong
  • HbA1c reduction — up to 1.16% reduction at highest doses in phase 2 trialsmoderate
  • Weight loss — 4–10 kg over 16–32 weeks in phase 2 dose-ranging studiesmoderate
  • Non-peptide structure — small molecule may be cheaper to manufacture at scale than biologic peptidespreliminary
  • No cold chain requirement — oral tablets are stable at room temperature unlike some injectable peptide formulationspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral tablet (immediate-release, phase 2)2.5–120 mgTwice dailyPhase 2 tested doses from 2.5 mg to 120 mg twice daily with dose escalation. High GI side effect burden at upper doses. This formulation has been deprioritized.
Oral tablet (modified-release, current development)Dose TBDOnce dailyPfizer is developing a modified-release once-daily formulation designed to reduce peak plasma concentrations and improve GI tolerability. Phase 2b results expected in 2026.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea — very common (40–60% in phase 2), leading to high discontinuation rates with immediate-release formulationcommon
  • Vomiting — reported in 20–30% of patients on immediate-release formulationcommon
  • Diarrhea — gastrointestinal effects in 15–25% of patientscommon
  • Decreased appetite — reported in 10–15% of patients; considered a therapeutic effect for weight losscommon
  • High discontinuation rate — 40–50% dropout in phase 2 with twice-daily dosing due to GI intoleranceserious

Frequently Asked Questions

How does danuglipron differ from oral semaglutide (Rybelsus)?
Oral semaglutide (Rybelsus) is still a peptide that requires SNAC absorption enhancer, must be taken fasting with minimal water, and cannot be taken with other oral medications for 30 minutes. Danuglipron is a small molecule with conventional oral absorption — no fasting requirement, no water restrictions, and can be taken with food. However, oral semaglutide is already approved and proven, while danuglipron remains in clinical development with significant GI tolerability challenges.
Why did Pfizer switch from twice-daily to once-daily danuglipron?
Phase 2 trials with twice-daily danuglipron showed a 40–50% discontinuation rate, primarily due to gastrointestinal side effects (nausea, vomiting). The modified-release once-daily formulation aims to reduce peak drug levels (Cmax) while maintaining therapeutic exposure (AUC), theoretically smoothing the pharmacokinetic profile and reducing GI stimulation. This is similar to how extended-release exenatide (Bydureon) improved tolerability over immediate-release exenatide (Byetta).
Could danuglipron be cheaper than injectable GLP-1 RAs?
Small molecule drugs are generally cheaper to manufacture than biologic peptides, which require complex synthesis or fermentation. If danuglipron reaches market, manufacturing costs could be significantly lower than semaglutide or tirzepatide. However, pricing decisions depend on many factors beyond manufacturing cost: development costs, market positioning, patent landscape, and competitive dynamics. Pfizer has not indicated planned pricing.
How does danuglipron compare to Eli Lilly's orforglipron?
Both are oral non-peptide GLP-1 RA small molecules, but they are at different development stages and show different profiles. Orforglipron (Eli Lilly) completed phase 3 with promising results showing up to 14.7% weight loss and is closer to FDA submission. Danuglipron (Pfizer) had significant GI tolerability issues in phase 2 and pivoted to a modified-release formulation, putting it further behind. Orforglipron currently appears to have a clinical development advantage.
Is danuglipron still being developed?
Yes, as of early 2026, Pfizer continues development of the modified-release once-daily danuglipron formulation. After disappointing tolerability with the twice-daily version, Pfizer invested in reformulation. The company has described danuglipron as a key pipeline asset in the obesity/metabolic space, though it lags behind competitors. Phase 2b results for the modified-release formulation are expected to determine whether the program advances to phase 3.

References

  1. 1
    Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial(2021)PubMed ↗
  2. 2
    Safety and efficacy of danuglipron in type 2 diabetes: a dose-ranging phase 2b trial(2023)PubMed ↗
  3. 3
    Small-molecule GLP-1 receptor agonists: discovery and development landscape(2022)PubMed ↗
  4. 4
    Oral nonpeptide GLP-1R agonists: from concept to clinical development(2022)PubMed ↗

Latest Research

Last updated: 2026-02-19